Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA gyrase and DNA topoisomerase IV are essential bacterial type II topoisomerases that manage DNA topology during replication, transcription, and chromosomal segregation. DNA gyrase uniquely introduces negative supercoils and relaxes positive supercoils, while topoisomerase IV mainly decatenates intertwined daughter chromosomes and also relaxes supercoils. Both are heterotetrameric enzymes: gyrase is composed of GyrA and GyrB subunits, topoisomerase IV of ParC and ParE subunits. These enzymes are validated and clinically important antibacterial targets, especially for fluoroquinolones and newer drug classes. The widespread clinical use of these inhibitors has led to high rates of target-mediated resistance, making continued drug development against these targets a central focus in antibacterial chemotherapy.
Stabilization of topoisomerase-DNA cleavage complexes leading to double-stranded DNA breaks (fluoroquinolones and related agents) Inhibition of ATPase activity (aminocoumarins) Allosteric inhibition (NBTIs)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNA topoisomerase II and topoisomerase IV (DNA gyrase (often abbreviated as Gyrase) and topoisomerase IV (Topo IV)).